PeopleAndrew Edge

Andrew is a corporate partner who advises on public and private M&A, joint ventures and equity fundraisings.

Andrew was the lead partner working on the deal that was shortlisted for corporate deal of the year 2010/11 by Legal Business magazine and is ranked as a leading 'life sciences' M&A lawyer by the Chambers & Partners' legal guide.

Prior to joining Stephenson Harwood in 2010, Andrew was partner for eight years in another major international law firm.

Transactions on which Andrew has advised include:

• Piramal Healthcare - $3.7 billion disposal of its generic branded prescription pharmaceuticals division to Abbott
• Nicholas Piramal India Limited (now Piramal Healthcare Limited) - acquisition of Pfizer's Northumberland manufacturing plant
• FTSE-250 speciality pharmaceutical company, BTG plc - £177 million public takeover of Biocompatibles International plc
• Lavendon Group plc - successful defence against a hostile approach from TVH Services NV and Ashtead Group plc
• Lavendon Group plc - £250 million debt refinancing and placing and open offer
• GDF SUEZ - The world's largest utility company - disposal of the Logan Teleflex group of companies to Tokyo-listed company Daifuku
• Commerzbank - disposal of Kleinwort Benson to RHJ International 
• United Company Rusal Limited and its largest shareholder, EN+ Group Limited - $14 billion acquisition of a 25 per cent stake in Moscow-listed copper and nickel miner Norilsk Nickel
• Rusal Limited - $30 billion combination with Sual and the alumina assets of Glencore International, to form United Company Rusal, the world's largest aluminium producer
• Biopharmaceutical company, Protherics plc - acquisition by BTG plc

Andrew has been highlighted as a leading lawyer in his field in the 2012 'The Lawyer Hot 100' report. To see a copy of the report, please click here.

Back to profile